List view / Grid view
The acquisition is set to strengthen BioNTech’s capabilities in development…
The acquisition is set to strengthen BioNTech’s capabilities in development and manufacture of next-generation bispecific antibodies.
Pfizer and BioNTech’s adapted Omicron XBB.1.5 COVID-19 vaccine has been…
Pfizer and BioNTech’s adapted Omicron XBB.1.5 COVID-19 vaccine has been recommended for two additional indications in the EU.
Signing of a major agreement between BioNTech SE and the…
Signing of a major agreement between BioNTech SE and the UK government for cancer trials means more patients could access personalised immunotherapies.
The UK Government and BioNTech’s new partnership aims to accelerate…
The UK Government and BioNTech’s new partnership aims to accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines.
BioNTech will evaluate mRNA vaccine manufacturing facilities in Rwanda and…
BioNTech will evaluate mRNA vaccine manufacturing facilities in Rwanda and Senegal to support vaccine supply in African states.
The COVID-19 vaccine candidate BNT162b2, made by Pfizer and BioNTech,…
The COVID-19 vaccine candidate BNT162b2, made by Pfizer and BioNTech, has demonstrated over 90 percent efficacy in its first interim analysis during its Phase III trial.
